KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate 

Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences

WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera, under their strategic collaboration agreement. As a result, Kymera will realize a $45 million milestone payment. Gilead will progress the program into IND-enabling studies to support an IND filing in 2027.